European Lung Cancer Working Party Clinical Practice Guidelines Non-small Cell Lung Cancer: II. Unresectable Non-metastatic Stages

The present guidelines on the management of unresectable non-metastatic non-small cell lung cancer (NSCLC) were formulated by the ELCWP in October 2005. They are designed to answer the following eight questions: 1) Is chest irradiation curative for NSCLC? 2) What are the contra-indications (anatomical or functional) to chest irradiation? 3) Does the addition of chemotherapy add an advantage to radiotherapy? 4) Does the addition of radiotherapy add an advantage to chemotherapy? 5) Is irradiation as effective as surgery for marginally resectable stage III? 6) How to best combine chemotherapy with radiotherapy: sequentially, concomitantly, as consolidation, as induction, as radiosensitiser? 7) In case of too advanced locoregional disease, is there a role for consolidation (salvage) local treatment (surgery or radiotherapy) after induction chemotherapy? 8) In 2005, what are the technical characteristics of an adequate radiotherapy

European Lung Cancer Working Party. Clinical Practice Guidelines. Small Cell Lung Cancer: V. Extensive disease

The present guidelines on the management of extensive disease small cell lung cancer (SCLC) were formulated by the ELCWP in October 2007. They are designed to answer the following nine questions: 1) What is the definition of extensive disease? 2)What are the active drugs? 3) What is the best induction regimen? 4) Is there a role for maintenance chemotherapy? 5) Is there a role for dose-intensive chemotherapy? 6) Is there a role for the use of haemopoietic growth factors and stem cells support? 7) Is there a role for alternating or sequential chemotherapy? 8) Is there a role for biological treatments? 9) Is there a place for second-line chemotherapy

European Lung Cancer Working Party Clinical Practice Guidelines. Non-Small Cell Lung Cancer: III. Metastatic disease

The present guidelines on the management of advanced non-small cell lung cancer (NS CLC) were formulated by the ELCWP in October 2006. They are designed to answer the following twelve questions: 1) What benefits can be expected from chemotherapy and what are the treatment objectives? 2) What are the active chemotherapeutic drugs for which efficacy has been shown? 3) Which are the most effective platinum-based regimens? 4) Which is the indicated dosage of cisplatin? 5) Can carboplatin be substituted for cisplatin? 6) Which is the optimal number of cycles to be administered? 7) Can non-platinum based regimens be substituted for platinum based chemotherapy as first-line treatment? 8) Is there an indication for sequential chemotherapy? 9) What is the efficacy of salvage chemotherapy and which drugs should be used in that indication? 10) What is the place of targeted therapies? 11) What is the place of chemotherapy in the management of a patient with brain metastases? 12) Which specific drugs can be used for the patient with bone metastases

Le syndicalisme alsacien et mosellan, de l’Allemagne à la France (1914-1920)

International audienc

Le syndicalisme alsacien et mosellan, de l’Allemagne à la France (1914-1920)

International audienc

European Lung Cancer Working Party Clinical Practice Guidelines. Non-small cell lung cancer: I. Early stages

The present guidelines on the management of resectable non-small cell lung cancer (NSCLC) were formulated by the (ELCWP) in April 2005. They aim in answering the following eleven questions: 1) Is surgery the best therapy for a potentially resectable cancer? 2) How is complete resection defined? 3) Is systematic lymph node dissection necessary during surgery? 4) What is the role of radiotherapy after complete resec tion? 5) Should adjuvant or neoadjuvant chemotherapy be administered in clinical stages I or II? 6) Should adjuvant chemotherapy be administered in pathological stages I or II? 7) Is adjuvant therapy advisable after complete resection for pathologi cal stage IIIA N2? If yes, of what type: chemotherapy, radiotherapy or chemotradio herapy? 8) What are the indications for surgery after induction treatment, in clinical stages IIIA or IIIB? 9) In clinical stages IIIA or IIIB, is preoperative therapy required and of what type? 10) What type of treatment is indicated after an incomplete surgical resection? 11) What is the best regimen for (neo)adjuvant chemotherapy

Un exemple du développement de l'approche pluridisciplinaire en archéologie sous-marine : l'épave Aber Wrac'h 1

L'Hour Michel, van de Moortel Aleydis, Richez Florence, Veyrat Elisabeth, Daveau Isabelle, Rival Michel, Roman Robert, Bompaire Marc, Froget Claude, Guibal Frédéric, Jovet-Ast Simone, Bailly Gilles, Migaud Philippe, Perez Magali, Plu Arlette, Querré Guirec, Ruas Marie-Pierre, Sternberg Myriam, Evin Jacques. Un exemple du développement de l'approche pluridisciplinaire en archéologie sous-marine : l'épave Aber Wrac'h 1. In: Bulletin de la Société préhistorique française, tome 86, n°10-12, 1989. Du terrain au laboratoire : Pour un meilleur dialogue en archéologie. pp. 451-457

Carfilzomib Weekly plus Melphalan and Prednisone in Newly Diagnosed Transplant-Ineligible Multiple Myeloma (IFM 2012-03): A Phase I Trial.

Carfilzomib is a novel generation proteasome inhibitor. The Carmysap trial demonstrated that twice-weekly KMP (carfilzomib, melphalan, prednisone) might challenge the MPV (melphalan, prednisone, bortezomib) standard. We sought to study KMP weekly, allowing to increase carfilzomib's dose with maintained efficacy and improved safety profile.info:eu-repo/semantics/publishe

Carfilzomib maintenance in newly diagnosed non-transplant eligible multiple myeloma

International audienc

Neuropathic Aspects of Persistent Postsurgical Pain: A French Multicenter Survey With a 6-Month Prospective Follow-Up

International audienc